-

New Thermo Fisher Scientific™ TSG Series Refrigerators Reduce Waste and Save Energy

TSG Series Laboratory and Pharmacy Refrigerators are designed and constructed sustainably in a zero-waste facility, offering a cleaner alternative and improved performance at a lower cost.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, announced today a new line of Thermo Scientific TM TSG Series Refrigerators to ensure the safe storage of critical vaccines and pharmaceuticals for laboratory, pharmacy and clinical* environments.

The World Health Organization estimates that up to 50% of vaccines are wasted each year globally, primarily due to temperature control, logistics and shipment-related issues. The result is less vaccine availability for patients and caregivers and financial loss to physicians, researchers and institutions. TSG Series Laboratory and Pharmacy Refrigerators provide safe, effective storage of vaccines and other pharmaceuticals with less vaccine waste for our customers and is manufactured at our zero-waste-to-landfill facility in Asheville, North Carolina.

This new TSG series complies with NSF 456 performance standards, an American national standard that helps ensure storage equipment performs as intended to preserve the viability of vaccine doses. Compliance requires that vaccine storage equipment is tested against a rigorous protocol for construction and performance. The TSG series achieves this through optimum temperature performance, enhanced sample security, and an extended warranty doubled over previous models with full parts and labor.

“At Thermo Fisher Scientific, we’ve been providing our customers with cold storage solutions they can rely on for more than 80 years,” said Carlos Sevilla, Vice President and General Manager, Controlled Temperature Technologies. “The TSG Series is cost-effective, reliable, and provides greater energy efficiency and less vaccine waste, enabling our customers to make the world healthier, cleaner and safer.”

TSG Refrigerators also provide a 10% reduction in energy usage from previous models. They are Energy Star, EU F-Gas and U.S. EPA SNAP compliant and designed and constructed sustainably at a zero-waste facility in the U.S., furthering Thermo Fisher’s commitment to achieve Net-Zero Carbon Emissions by 2050.

For detailed product information and to order it now, click here.

*Note: These products are not considered as medical devices and have not been evaluated for use in environment or applications involving the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man or other animals.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Shannon Stoneking
Phone: 484-748-1279
Email: Shannon.Stoneking@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Shannon Stoneking
Phone: 484-748-1279
Email: Shannon.Stoneking@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc...

Thermo Fisher Scientific Announces Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier...

Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company’s industry leadership and the essential role of its best-in-class products and services to customers around the world. "Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive office...
Back to Newsroom